OKYO Pharma Limited's (LON:OKYO)(OTCQB:EMMLF) Dr Gary Jacob speaks to Proactive's Andrew Scott soon after announcing that a non-opioid analgesic they're developing has shown pre-clinical potential to treat acute and chronic ocular pain. OK-201 was assessed using a mouse neuropathic corneal pain model developed by Dr Pedram Hamrah, an ophthalmologist, cornea specialist, and clinician-scientist at Tufts Medical Center and professor of ophthalmology at Tufts University School of Medicine, Boston.
OKYO Pharma CEO talks promising pre-clinical data for its acute and chronic ocular pain drug
